Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.04
Nov 18 • 4:00 PM ET Dollar change+0.03 Percentage change(2.97%)
Aftermarket Close
1.03
Aftermarket • 5:41 PM ET Dollar change-0.01 Percentage change(-0.96%)
Index
-
Market Cap
13.90M
Enterprise Value
-8.25M
Income
-26.66M
Sales
0.00M
Book/sh
1.65
Cash/sh
1.67
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
12
IPO
Jan 31, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.63
P/C
0.62
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.87
Current Ratio
2.86
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-2.67
EPS next Y
-1.55
EPS next Q
-0.46
EPS this Y
32.46%
EPS next Y
29.39%
EPS next 5Y
15.53%
EPS past 3/5Y
61.55% -
Sales past 3/5Y
- -
EPS Y/Y TTM
67.96%
Sales Y/Y TTM
-100.00%
EPS Q/Q
17.88%
Sales Q/Q
-
Insider Own
24.71%
Insider Trans
0.00%
Inst Own
27.12%
Inst Trans
-13.42%
ROA
-85.24%
ROE
-123.08%
ROIC
-172.49%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
3.32%
SMA50
-11.98%
SMA200
-59.17%
Trades
Shs Outstand
13.36M
Shs Float
10.06M
52W High
5.69 -81.72%
52W Low
0.77 34.56%
Volatility
10.70% 15.03%
ATR (14)
0.15
RSI (14)
47.15
Beta
0.22
Rel Volume
0.29
Avg Volume
237.21K
Volume
69,626
Perf Week
-22.39%
Perf Month
4.84%
Perf Quarter
-43.17%
Perf Half Y
-72.99%
Perf YTD
-75.81%
Perf Year
-74.76%
Perf 3Y
-97.37%
Perf 5Y
-99.80%
Perf 10Y
-99.76%
Prev Close
1.01
Price
1.04
Change %
2.97%
Consensus
Buy
Avg. Price Target
$8.75
Implied Upside
+741.3%
Analysts12incl. previous ratings
Rating Distribution6 Buy · 4 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 20, 2026Initiated
CChardan Capital Markets
Buy$8+669.2%
Jul 08, 2026Upgrade
RJF logoRRaymond James
Mkt Perform → Outperform$10+861.5%
Jul 08, 2026Upgrade
PPiper Sandler
Neutral → Overweight$13+1,150.0%
Jun 08, 2026Initiated
HH.C. Wainwright
Buy$9+765.4%
Apr 20, 2026Downgrade
BCS logoBBarclays
Equal Weight → Underweight$3+188.5%
Oct 14, 2025Downgrade
RJF logoRRaymond James
Outperform → Mkt Perform
Oct 14, 2025Downgrade
BCS logoBBarclays
Overweight → Equal Weight$5+380.8%
Oct 13, 2025Initiated
BCS logoBBarclays
Overweight$61+5,765.4%
Oct 13, 2025Downgrade
PPiper Sandler
Overweight → Neutral$78 → $4+284.6%
Oct 13, 2025Downgrade
CCantor Fitzgerald
Overweight → Neutral
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX.
CEO & DirectorDr. Imran Alibhai Ph.D.
M.B.A.Mr. Dan Conn J.D.
Chief Medical OfficerDr. John Kauh M.D.
Co-Founder & Scientific Advisory Board MemberMr. David J. Tweardy M.D.
Co-Founder & Chairman of Scientific Advisory BoardDr. Ronald A. DePinho M.D.